Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2006-04-04
2006-04-04
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093200, C424S093210, C435S320100, C435S325000, C435S440000, C435S455000, C514S04400A
Reexamination Certificate
active
07022319
ABSTRACT:
The present invention relates to recombinant vectors carrying sequences encoding naturally occurring antimicrobial peptides or derivatives thereof for the treatment of mammalian tumours and viral infections such as HIV infections and bacterial and fungal infections. In particular the present invention relates to retroviral vectors. Furthermore, the present invention relates to retroviral vectors which undergo promoter conversion (Procon vectors) carrying such sequences. Since these vectors also carry tumour or virus specific regulatory elements, the therapeutic antimicrobial peptide will be delivered and expressed only in relevant, affected cells and not in innocent bystander cells.
REFERENCES:
patent: 4822608 (1989-04-01), Benton et al.
patent: 5124263 (1992-06-01), Temin et al.
patent: 5658775 (1997-08-01), Gilboa
patent: 5863904 (1999-01-01), Nabel et al.
patent: 5962410 (1999-10-01), Jaynes et al.
patent: 6022735 (2000-02-01), Curiel et al.
patent: 6027722 (2000-02-01), Hodgson
patent: 0415731 (1991-03-01), None
patent: WO 89/11539 (1989-11-01), None
patent: WO 91/08753 (1991-06-01), None
patent: WO 93/07906 (1993-04-01), None
patent: WO 93/12251 (1993-06-01), None
patent: WO 94/29437 (1994-12-01), None
patent: WO 95/00178 (1995-01-01), None
patent: WO 95/01095 (1995-01-01), None
patent: WO 95/06415 (1995-03-01), None
patent: WO 95/13375 (1995-05-01), None
patent: WO 96/07748 (1996-03-01), None
patent: WO 96/28564 (1996-09-01), None
patent: WO 96/37623 (1996-11-01), None
patent: WO 97/01357 (1997-01-01), None
patent: WO 97/09440 (1997-03-01), None
patent: WO 99/20742 (1999-04-01), None
patent: WO 99/35280 (1999-07-01), None
Verma et al. Gene Therapy- Promises, Problems and Prospects. Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
Orkin et al. Report and Recommendations of the Panel to Access the NIH Investment in Research on Gene Therapy. Distributed by the National Institutes of Health, Bethesda, MD or www.nih.gov, Dec. 7, 1995.
Dougherty et al. A Promoterless Retroviral Vector Indicates that there are Sequences in U3 Required for 3'RNA Processing. PNAS, vol. 84, pp. 1197-1201, Mar. 1987.
Perez-Paya et al. Biochem J 1994 Apr..;299:587-91.
Perez-Paya et al. Pept Res 1994 7:286-8.
Perez-Paya et al. J Biochem 1995 270:1048-56.
Rivett et al. Biochem J 1996; 316:525-29.
Peptides, Encyclopedia Britannica online, accessed Dec. 19, 2000.
Günzburg, W. H., et al., “Retroviral Vectors Directed to Predefined Cell Types for Gene Therapy,”Biologicals, 23:5-12 (1995).
Boman, H. G., “Peptide Antibiotics and Their Role in Innate Immunity,”Annu. Rev. Immunol., 13:61-92 (1995).
Moore, A.J., et al., “Preliminary Experimental Anticancer Activity of Cecropins,”Peptides Res., 7(5):265-269 (1994).
Sharma, S.V., “Melittin-induced hyperactivation of phospholipase A2activity and calcium influx in ras-transformed cells,”Oncogene, 8:939-947 (1993).
Sharma, S.V., “Melittin resistance: a counterselection for ras transformation,”Oncogene, 7:193-201 (1992).
Ohsaki, Y., et al., “Antitumor Activity of Magainin Analogues Against Human Lung Cancer Cell Lines,”Cancer Res., 52:3534-3538 (1992).
Wachinger, M. et al., “Influence of amphipathic peptides on the HIV-1 production in persistently infected T lymphoma cells,”FEBS, 309(3):235-241 (1992).
Cruciani, R. A., et al., “Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formatiom,”Proc. Natl. Acad. Sci. USA, 88:3792-3796 (1991).
Lee, J. -Y., et al., “Antibacterial peptides from pig intestine: Isolation of a mammalian cecropin,”Proc. Natl. Acad. Sci. USA, 86:9159-9162 (1989).
Vlasak, R., et al., “Nucleotide sequence of cloned cDNA coding for honeybee prepromelittin,”Eur. J. Biochem., 135:123-126 (1983).
Hultmark, D., et al., “Insect Immunity: Isolation and Structure of Cecropin D and Four Minor Antibacterial Components from Cecropia Pupae,”Eur. J. Biochem., 127:207-217 (1982).
Steiner, H., et al., “Sequence and specificity of two antibacterial proteins involved in insect immunity,”nature, 292:246-248 (1981).
Hultmark, D., et al., “Insect Immunity. Purification and Properties of Three Inducible Bactericidal Proteins from Hemolymph of Immunized Pupae ofHyalophora cecropia,” Eur. J. Biochem., 106:7-16 (1980).
Acha-Orbea et al., “Subversion of Host Immune Responses by Viral Superantigens”,Trends In Microbiology, vol. 1 (No. 1); 32-34, Apr. 1993.
Knight et al., “Biochemical Analysis of the Mouse Mammary Tumor Virus Long Terminal Repaet Product. Evidence for the Molecular Structure of an Endogenous Superantigen”,European Journal of Immunology, vol. 22; 879-882, 1992.
Salmons et al., “Production of Mouse Mammary Tumor Virus upon Transfection of a Recombinant Proviral DNA into Cultured Cells”,Virology, vol. 144; 101-114, 1985.
Korman et al., “The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes a Type II Transmembrane Glycoprotein”,The EMBO Journal, vol. 11 (No. 5); 1901-1905, 1992.
Hornsby et al., “A Modified Procedure for Replica Plating of Mammalian Cells Allowing Selection of Clones Based on Gene Expression”,BioTechniques, vol. 12 (No. 2); 244-251, 1992.
Günzburg et al., “Factors Controlling the Expression of Mouse Mammary Tumour Virus”,Biochemical Journal, vol. 283; 625-632, 1992.
Huber, Brigitte T., “Mls Genes and Self-Superantigens”,TIG, vol. 8 (No. 11); 399-402, Nov. 1992.
Salmons et al., “Current Perspectives in the Biology of Mouse Mammary Tumour Virus”,Virus Research, vol. 8; 81-102, 1987.
Wintersperger, et al., “Negative-acting Factor and Superantigen Are Separable Activities of the Mouse Mammary Tumor Virus Long Terminal Repeat”,Proceedings of the National Academy of Sciences; vol. 92; 2745-2749, Mar. 1995.
Donehower et al., “Regulatory and Coding Potential of the Mouse Mammary Tumor Virus Long Terminal Redundancy”,Journal of Virology, vol. 37 (No.1): 226-238, Jan. 1981.
Vile et al., “In Vitro and In Vivo Targeting of Gene Expression to Melanoma Cells”,Cancer Research, vol. 53 (No. 5); 962-967 (abstract only), 1993.
Choi et al., “A Superantigen Encoded in the Open Reading Frame of the 3' Long Terminal Repeat of Mouse Mammary Tomour Virus”,Nature, vol. 350; 203-207, Mar. 1991.
Brandt-Carlson et al., “Detection and Characterization of a Glycoprotein Encoded by the Mouse Mammary Tumor Virus Long Terminal Repeat Gene”,Journal of Virology, vol. 65 (No. 11); 6051-6060, Nov. 1991.
Acha-Orbea et al., “Clonal Deletion of V β14-bearing T Cells In Mice Transgenic for Mammary Tumour Virus”,Nature, vol. 350; 207-211, Mar. 1991.
Brandt-Carlson et al., “Phylogenetic and Structural Analyses of MMTV LTR ORF Sequences of Exogenous and Endogenous Origins”,Virology, vol. 193, 171-185, 1993.
Krummenacher et al., “The Mouse Mammary Tumor Virus Long Terminal Repeat Encodes A 47 kDa Glycoprotein With A Short Half-life In Mammalian Cells”,Molecular Immunology, vol. 30 (No. 13); 1151-1157, 1993.
Winslow et al., “Detection and Biochemical Characterization of the Mouse Mammary Tumor Virus 7 Superantigen (Mls-1a)”,Cell, vol. 71; 719-730, Nov. 1992.
Winslow et al., “Processing and Major Histocompatibility Complex Binding of the MTV7 Superantigen”,Immunity, vol. 1; 23-33, Apr. 1994.
Kay et al., “In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-deficient Dogs”,Science, vol. 262 (No. 5130); 117-119, Oct. 1993.
Pullen et al., “The Open Reading Frames in the 3' Long Terminal Repeats of Several Mouse Mammary Tumor Virus Integrants Encode Vβ3-specific Superantigens”,Journal of Experimental Medicine, vol. 175; 41-17, Jan. 1992.
Mohan et al., “Production and Characterization of an Mls-1-specific Monoclonal Antibody”,Journal of E
Günzburg Walter H.
Saller Robert M.
Winder David
GSF - Forschungszentrum fuer Umwelt und Gesundheit GmbH
Jenkins & Wilson & Taylor, P.A.
Li Q. Janice
LandOfFree
Vectors carrying therapeutic genes encoding antimicrobial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectors carrying therapeutic genes encoding antimicrobial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectors carrying therapeutic genes encoding antimicrobial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3617421